Sunesis Pharmaceuticals (SNSS) Misses Q4 EPS by 1c

Sunesis Pharmaceuticals (NASDAQ: SNSS) reported Q4 EPS of ($0.44), $0.01 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $600 thousand.

For earnings history and earnings-related data on Sunesis Pharmaceuticals (SNSS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c